Meet the latest Harvard Business School Blavatnik Fellows: Hunter Goble
With its spirited motto that “The science of today is the business of tomorrow,” the Blavatnik Fellowship in Life Science Entrepreneurship at the Harvard Business School (HBS) recently named five new fellows.
Established in 2013 and supported by the Blavatnik Family Foundation, the one-year program offers Harvard alumni and Harvard-affiliated postdoctoral researchers practical materials. The fellowship provides access to strategic resources to create new ventures around promising life science technologies while developing leadership talents.
Hunter Goble, one of the fellows for 2022-2023, will work with Harvard inventors and Harvard-affiliated hospitals to promote the commercialization of life science technologies with significant market potential.
Bio: Before HBS, Goble interned and later worked at Eli Lilly and Co. in a marketing rotational program, commercializing biologic therapies for autoimmune diseases. He also worked at Huron Consulting Group and Cured, a health tech startup. Goble earned his bachelor’s from DePauw University in political science. He recently earned his MBA from HBS.
The innovation: Goble is the co-founder and CEO of Transcera, a biotech startup harnessing the biology of sphingolipids, a class of lipids, to enable oral delivery and amplified distribution of biologic medicines. The Blavatnik Fellowship will help Globe refine business strategy and development for the company’s novel drug delivery platform with his co-founders, Harvard Medical School Professor Dr. Wayne Lencer and Justin Wolfe, Ph.D.
Looking ahead: Goble said, “The support of the Blavatnik Family Foundation alleviates some of the personal risk endemic to entrepreneurship in life sciences. It has empowered me to chase a career dream I never thought possible, and it bolsters our chances of success in a meaningful way.”
What others are saying: “I am excited to work with [the Blavatnik Fellows] and carry on the program’s mission to inspire young life science entrepreneurs as they enter the Boston biotech ecosystem as Blavatnik Fellows,” said Peter Barrett, Ph.D., faculty chair and leader of the HBS Blavatnik Fellowship.
Spurring investment: Since 2013, Blavatnik fellows have created 30 companies, developing, among other things, a precision gene therapy, a respiratory dialysis device, a femtech device using genomics to enable women’s care, a biosensing wearable to prevent dehydration, and an oxygen sensor for personalized oncology care. They have collectively raised more than $485 million in funding and an additional $244 million from an IPO in June 2020.